Company Reports & Presentations | GeneType | Genetic Technologies

Company Reports & Presentations

ASX Reports Quarterly

Appendix 4C 30 September 2022
Appendix 4C 30 June 2022
Appendix 4C 31 March 2022
Appendix 4C 30 June 2021
Appendix 4C 31 March 2021

ASX Reports Half-Yearly

Half-year ended 31 Dec 2021

Appendix 4G – June 2021

Appendix 4G & Corporate Governance Statement

Form 20-F

Form 20-F October 2020

Company news and Investor Presentations

Genetype Business Update Q1 FY23
GTG BioInvest Presentation - 27 October 2022
Coffee Microcaps Business Update September 2022
MST Access Initiation report on Genetic Technologies Sept 2022
Genetic Technologies Business Update September 2022
Genetype Business Update Q4 FY22
Investor update April 2022
Quarterly Investor presentation January 2022
Presentation to HC Wainwright & Co 23nd Annual Global Investment Conference
CEO Investor update – Q4 Results – July 2021 Presentation & webinar
Meet the CEO March 2021
Quarterly Investor presentation January 2021
AGM presentation 10 December 2020
Presentation to Shareholders 30 October 2020
Presentation to HC Wainwright & Co 22nd Annual Global Investment Conference
US sales commence via Online Health Platform September 2020
Presentation to JP Morgan Biotech Showcase, San Francisco, Jan 2020

ASX Reports Annual

Annual Report ended 30 June 2022
Annual Report ended 30 June 2021
Annual Report ended 30 June 2020
Annual Report ended 30 June 2019
Annual Report ended 30 June 2018

Newswire Articles

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer
GENE Momentum building - a year in review
Gene achieves key milestones and growth
GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians
Completion of AffinityDNA Acquisition expanding global direct-to-consumer business
EasyDNA expands Indian and European markets; launching NIPT, Carrier testing and DNA storage
GeneType Risk Assessment Test onboarding in 16 clinics
Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer Risk Assessment Test
Acquisition of global direct to consumer ecommerce business
Genetic Technologies drives leadership in precision medicine with Multi-Risk Test
GeneType Multi-Test Receives Regulatory Approval for Commercial Release in USA and Australia
US Patent Office Grants Patent for COVID-19 Risk Test
MedRxiv – An integrated clinical and genetic model for predicting risk of severe COVID-19
Global Newswire Media release September 2020
Global Newswire Media release July 2020
Lodge Partners Research Report May 2020
Global Newswire Media release May 2020
Developing New COVID-19 Risk Assessment Test May 2020

Financial Reports

Half year end results (28 February 2022)
Financial year end (30 June 2021)
Full year results (31 August 2021)
AGM - Virtual (24 November 2021)
Half year end (31 December 2021)

Questions?

Contact our Investor Relations department.
Australia: justin.foord@marketeye.com.au